查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612567

生技藥品市場：按來源、產品、適應症和最終用戶分類 - 2025-2030 年全球預測

Biologics Market by Source (Mammalian, Microbial), Product (Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins), Indication, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年生技藥品市場價值為4057.6億美元，預計到2024年將達到4,305.9億美元，複合年成長率為6.39%，到2030年將達到6263.4億美元。

生技藥品是製藥業快速發展的一個領域，涵蓋生物來源，例如疫苗、血液成分、基因療法和單株抗體。慢性病的增加、生物技術的進步以及對標靶治療的需求強調了對生技藥品的需求。其應用範圍涵蓋癌症、類風濕性關節炎和多發性硬化症等疾病的治療，並用於醫院、研究機構和專科診所。關鍵的成長要素包括基因工程和細胞療法的持續創新，以及促進藥物快速核准的強力的監管支持。此外，製藥公司和生技新興企業之間的合作正在帶來突破，特別是在精準醫學和生物相似藥（一類提供更便宜的替代療法的藥物）方面。治療機會在於開發個人化治療方法和提高生產擴充性以滿足不斷成長的需求。然而，生技藥品市場面臨研發成本高、製造流程複雜、法規要求嚴格等限制，往往導致上市時間較長。一個關鍵的挑戰是保持產品的穩定性和一致性。市場參與企業的創新領域包括最佳化生物加工技術和利用人工智慧來簡化藥物發現和開發。強大的儲存和配送基礎設施對於克服低溫運輸的限制也至關重要。市場是動態的，進入障礙很高，成功創新的回報也很高。為了取得成功，公司應該注重策略聯盟，共用技術，簡化研發，並開拓醫療需求未被滿足的新興市場。駕馭此一局面需要平衡尖端科學發現與務實的供應鏈管理。

主要市場統計
基準年[2023] 4057.6億美元
預計年份 [2024] 4305.9億美元
預測年份 [2030] 6263.4億美元
複合年成長率（%） 6.39%

市場動態：揭示快速發展的生技藥品市場的關鍵市場洞察

供需的動態交互作用正在改變生技藥品市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球慢性病盛行率上升
    • 對微創手術的需求和偏好日益成長
  • 市場限制因素
    • 與生技藥品相關的治療成本上升
  • 市場機會
    • 生醫材料的持續進步改善慢性病的治療
    • 不斷擴大與生技藥品相關的生產設施
  • 市場挑戰
    • 生技藥品複雜製造的可能性

波特五力：駕馭生技藥品市場的策略工具

波特的五力架構是了解生技藥品市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生技藥品市場的外部影響

外部宏觀環境因素在塑造生技藥品市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解生技藥品市場的競爭格局

生技藥品市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生技藥品市場供應商的績效評估

FPNV定位矩陣是評估生技藥品市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃生技藥品市場的成功之路

對於希望加強在全球市場的影響力的公司來說，生技藥品市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地慢性病盛行率正在上升
      • 對微創手術的需求和偏好日益成長
    • 抑制因素
      • 與生技藥品相關的治療成本上升
    • 機會
      • 生物材料的持續進步改善慢性病的治療
      • 擴大生技藥品相關生產設施
    • 任務
      • 生技藥品複雜製造的可用性
  • 市場區隔分析
    • 資料來源：哺乳動物細胞更適合生產更大、更複雜的蛋白質
    • 適應症：由 COVID-19 大流行和癌症研究進展推動的腫瘤學和感染疾病的持續創新
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章生技藥品市場：依來源分類

  • 哺乳動物的
  • 微生物

第7章生技藥品市場：依產品

  • 反義和RNAi療法
  • 單株抗體
  • 重組激素或蛋白質
  • 疫苗

第8章生技藥品市場的適應症

  • 心血管疾病
  • 血液疾病
  • 免疫疾病
  • 感染疾病
  • 腫瘤學

第9章生技藥品市場：依最終用戶分類

  • 門診手術中心
  • 醫院

第10章美洲生技藥品市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太生技藥品市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的生技藥品市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准首個托珠單抗生物相似藥 TOFIDENCE，改善自體免疫疾病治療的可近性
    • 禮來公司擴大對愛爾蘭生技藥品製造工廠的投資
    • 山德士宣布對斯洛維尼亞新工廠進行重大投資
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Biogen Inc.
  • BioPharm Laboratories, LLC
  • Bristol Myers Squibb Company
  • Catalent, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Inc.
Product Code: MRR-4302AC72200D

The Biologics Market was valued at USD 405.76 billion in 2023, expected to reach USD 430.59 billion in 2024, and is projected to grow at a CAGR of 6.39%, to USD 626.34 billion by 2030.

Biologics, a rapidly expanding segment within the pharmaceutical industry, encompass a diverse range of products derived from living organisms, such as vaccines, blood components, gene therapy, and monoclonal antibodies. The increasing prevalence of chronic diseases, advancements in biotechnology, and the need for targeted therapies underscore the necessity of biologics. Their applications span across treating diseases like cancer, rheumatoid arthritis, and multiple sclerosis, serving hospitals, research institutions, and specialty clinics. Key growth influencers include ongoing innovations in genetic engineering and cell therapy, alongside robust regulatory support facilitating expedited drug approvals. Additionally, partnerships between pharmaceutical companies and biotech startups are yielding breakthroughs, particularly in precision medicine and biosimilars-a class of drugs offering more affordable therapeutic alternatives. Opportunities lie in developing personalized treatment approaches and enhancing production scalability to meet growing demand. However, the biologics market faces limitations such as high R&D costs, complex manufacturing processes, and stringent regulatory requirements which often prolong time-to-market transitions. A key challenge is maintaining product stability and consistency. For market players, innovative areas include optimizing bioprocessing techniques and harnessing artificial intelligence to streamline drug discovery and development. Robust infrastructure for storage and distribution is also vital to overcoming cold chain limitations. The market is dynamic, characterized by high barriers to entry but also high rewards for successful innovation. To thrive, businesses should focus on strategic alliances for technology sharing, enhancing R&D efficiencies, and exploring emerging markets with unmet medical needs. Navigating the biologics landscape requires balancing cutting-edge scientific discovery with pragmatic supply chain management-a challenge that, if met, promises significant growth potential in improving global health outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 405.76 billion
Estimated Year [2024] USD 430.59 billion
Forecast Year [2030] USD 626.34 billion
CAGR (%) 6.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Market

The Biologics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases worldwide
    • Growing need and preference for minimally invasive procedures
  • Market Restraints
    • High cost of treatment associated with biologics
  • Market Opportunities
    • Ongoing advancements in biomaterials improving the treatment of chronic disorders
    • Rising expansion of manufacturing facilities associated with biologics
  • Market Challenges
    • Availability of complex manufacturing of biologics

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Market

A detailed market share analysis in the Biologics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Market

A strategic analysis of the Biologics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Biogen Inc., BioPharm Laboratories, LLC, Bristol Myers Squibb Company, Catalent, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source, market is studied across Mammalian and Microbial.
  • Based on Product, market is studied across Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins, and Vaccines.
  • Based on Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, Infectious Diseases, and Oncology.
  • Based on End-user, market is studied across Ambulatory Surgical Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases worldwide
      • 5.1.1.2. Growing need and preference for minimally invasive procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment associated with biologics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in biomaterials improving the treatment of chronic disorders
      • 5.1.3.2. Rising expansion of manufacturing facilities associated with biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of complex manufacturing of biologics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Source: Mammalian cells are preferable for producing larger and more complex proteins
    • 5.2.2. Indication: Ongoing innovations in oncology and infectious diseases driven by the COVID-19 pandemic and cancer research's evolution
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Market, by Source

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Microbial

7. Biologics Market, by Product

  • 7.1. Introduction
  • 7.2. Antisense & RNAi Therapeutics
  • 7.3. Monoclonal Antibodies
  • 7.4. Recombinant Hormones or Proteins
  • 7.5. Vaccines

8. Biologics Market, by Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Disorders
  • 8.3. Hematological Disorders
  • 8.4. Immunological Disorders
  • 8.5. Infectious Diseases
  • 8.6. Oncology

9. Biologics Market, by End-user

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals

10. Americas Biologics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biologics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biologics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves First Tocilizumab Biosimilar, TOFIDENCE, Enhancing Access to Treatment for Autoimmune Diseases
    • 13.3.2. Eli Lilly Expands Investment in Irish Biologics Manufacturing Facility
    • 13.3.3. Sandoz Announces Major Investment in New Biologics Facility in Slovenia
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Becton, Dickinson and Company
  • 6. Biogen Inc.
  • 7. BioPharm Laboratories, LLC
  • 8. Bristol Myers Squibb Company
  • 9. Catalent, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Genentech, Inc.
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Innovent Biologics, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck KGaA
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Thermo Fisher Scientific Inc.
  • 21. Vertex Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY ANTISENSE & RNAI THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT HORMONES OR PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023